Key Proteo, Inc.
Mark Willig currently holds a significant role as the President, Chief Executive Officer, and Member of the Board of Directors at Key Proteo, Inc. Mark is also the Founder and Managing Partner at Blue Ocean Consulting, LLC - Life Sciences. In addition, Mark serves as the Chairman of the Board at AggioSergeant International and as a Board Advisor at LynxDx. With a background in communications from the University of Missouri-Columbia, Mark has held various executive positions in leading companies such as Alveo Technologies, Curative, CardioDx, Agendia, Exiqon A/S, and Thermo Fisher Scientific.
This person is not in any teams
Key Proteo, Inc.
Key Proteo is democratizing the early detection of rare but treatable genetic disorders through novel and accessible proteomic analysis. As a pioneering proteomics company, Key Proteo is initially focused on the early detection of treatable rare genetic disorders in newborns, with the goal of expanding newborn screening to identify extremely low abundance protein biomarkers that were previously undetectable. Many treatable genetic disorders are difficult to detect, but when found early, intervention can be enabled to help change the clinical course. Ultimately, our mission is to relieve suffering and save lives for patients and their families afflicted by rare but treatable genetic disorders through early screening.